{"id":"rosuvastatin-alone","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Muscle pain or myalgia"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"5-10","effect":"Headache"},{"rate":"1-2","effect":"Nausea"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This inhibition decreases hepatic cholesterol production, leading to upregulation of LDL receptors on hepatocytes and increased clearance of LDL cholesterol from the bloodstream. The net result is a significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:10.957Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary prevention of cardiovascular disease"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary artery disease"}]},"trialDetails":[{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Advanced Solid Malignancies","enrollment":41},{"nctId":"NCT07300280","phase":"PHASE1","title":"A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-29","conditions":"Healthy","enrollment":60},{"nctId":"NCT07460960","phase":"PHASE2","title":"TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men","status":"RECRUITING","sponsor":"Lomonosov Moscow State University Medical Research and Educational Center","startDate":"2026-03-05","conditions":"Erectile Dysfunction Due to Arterial Disease, Atheroscleroses, Erectile Disfunction","enrollment":150},{"nctId":"NCT07349394","phase":"PHASE1","title":"Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2026-01-12","conditions":"Cystic Fibrosis","enrollment":18},{"nctId":"NCT06982131","phase":"PHASE1","title":"A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-04","conditions":"Overweight, Obesity","enrollment":40},{"nctId":"NCT06686615","phase":"","title":"A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2025-02-12","conditions":"Primary Hypercholesterolemiia, Mixed Dyslipidemia","enrollment":2000},{"nctId":"NCT07088913","phase":"PHASE1","title":"A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT07446400","phase":"PHASE1","title":"A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-03-20","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT06696820","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Xiang Luo","startDate":"2024-11-29","conditions":"Acute Ischemic Stroke","enrollment":429},{"nctId":"NCT06979973","phase":"PHASE1","title":"A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-05-14","conditions":"Healthy","enrollment":24},{"nctId":"NCT07235748","phase":"PHASE1","title":"Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2025-10-07","conditions":"Healthy Adult Participants","enrollment":28},{"nctId":"NCT07222098","phase":"PHASE1","title":"A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-19","conditions":"Healthy","enrollment":16},{"nctId":"NCT06981299","phase":"PHASE1","title":"A Phase 1 Study of PROT-001.","status":"COMPLETED","sponsor":"Protego Biopharma Pty Ltd","startDate":"2025-05-29","conditions":"Healthy","enrollment":102},{"nctId":"NCT07158398","phase":"PHASE1","title":"Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate","status":"COMPLETED","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2025-10-31","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT05741372","phase":"NA","title":"A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-09-07","conditions":"Liver Cirrhosis","enrollment":28},{"nctId":"NCT07097831","phase":"PHASE1","title":"A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-10-09","conditions":"Hyperlipidemia","enrollment":16},{"nctId":"NCT04481789","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-10-17","conditions":"Healthy Adult Subjects","enrollment":84},{"nctId":"NCT07313124","phase":"PHASE2, PHASE3","title":"Comparative Study Between Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-12-15","conditions":"Cardiovascular Diseases (CVD)","enrollment":66},{"nctId":"NCT07316608","phase":"PHASE1","title":"A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-16","conditions":"Healthy Participants","enrollment":44},{"nctId":"NCT02675309","phase":"PHASE1","title":"A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-02","conditions":"Healthy","enrollment":28},{"nctId":"NCT07201545","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-07","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT07182383","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-09-29","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT05444556","phase":"PHASE1","title":"A Study of Imlunestrant (LY3484356) in Female Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-07-07","conditions":"Healthy","enrollment":113},{"nctId":"NCT05064488","phase":"PHASE1","title":"Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-10-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT07012629","phase":"PHASE3","title":"A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-26","conditions":"Covert Brain Infarction","enrollment":1652},{"nctId":"NCT06742853","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-12-20","conditions":"Dyslipidemia","enrollment":81},{"nctId":"NCT06948747","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-06","conditions":"Healthy Participants","enrollment":49},{"nctId":"NCT06813924","phase":"PHASE1","title":"A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-02-06","conditions":"Healthy Volunteers Sickle Cell Disease, Thalassemia","enrollment":37},{"nctId":"NCT04669041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-08","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT05906836","phase":"PHASE1","title":"A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-07-27","conditions":"Healthy","enrollment":28},{"nctId":"NCT06767345","phase":"PHASE4","title":"Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-05-12","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic","enrollment":408},{"nctId":"NCT06821698","phase":"PHASE1","title":"To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers","status":"COMPLETED","sponsor":"Kaken Pharmaceutical","startDate":"2025-02-13","conditions":"Healty Volunteers","enrollment":38},{"nctId":"NCT06949124","phase":"PHASE1","title":"A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-04-28","conditions":"Endometriosis, Uterine Fibroids, Assisted Reproduction","enrollment":20},{"nctId":"NCT06358313","phase":"PHASE3","title":"Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT06360120","phase":"PHASE3","title":"Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT06921941","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-08","conditions":"Healthy Volunteer Study","enrollment":38},{"nctId":"NCT06698666","phase":"PHASE3","title":"Efficacy of Statins Among Major Depressive Disorder","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2022-10-01","conditions":"Major Depressive Disorder, MDD","enrollment":145},{"nctId":"NCT07065058","phase":"PHASE1","title":"A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2025-07-01","conditions":"Obesity &Amp; Overweight","enrollment":24},{"nctId":"NCT06071442","phase":"PHASE1","title":"Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-17","conditions":"Healthy Participants","enrollment":60},{"nctId":"NCT06567327","phase":"PHASE1","title":"A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-08-28","conditions":"Obesity","enrollment":82},{"nctId":"NCT04499859","phase":"PHASE4","title":"Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI","status":"RECRUITING","sponsor":"Kiyuk Chang, MD,PhD","startDate":"2020-10-01","conditions":"Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity","enrollment":3548},{"nctId":"NCT06491550","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-07-15","conditions":"Healthy Participants","enrollment":91},{"nctId":"NCT06917508","phase":"PHASE1","title":"A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Enanta Pharmaceuticals, Inc","startDate":"2025-03-13","conditions":"RSV Infection, Drug Drug Interaction","enrollment":24},{"nctId":"NCT03359291","phase":"PHASE1","title":"Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-11-03","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT06925854","phase":"PHASE1","title":"A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Healthy","enrollment":12},{"nctId":"NCT07001787","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-06","conditions":"Dyslipidemia","enrollment":88},{"nctId":"NCT04008186","phase":"PHASE1","title":"A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-06-14","conditions":"Healthy Adult Subjects","enrollment":61},{"nctId":"NCT01598363","phase":"PHASE1","title":"An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-06-30","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT06335134","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-07-14","conditions":"Healthy Volunteers","enrollment":57},{"nctId":"NCT06048588","phase":"PHASE1, PHASE2","title":"YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis","status":"COMPLETED","sponsor":"Beijing Inno Medicine Co., Ltd.","startDate":"2023-10-08","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":144},{"nctId":"NCT05787002","phase":"PHASE1","title":"A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-03-09","conditions":"Dyslipidemia","enrollment":16},{"nctId":"NCT06767774","phase":"PHASE4","title":"Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-04-25","conditions":"ASCVD, Diabetes, Statin","enrollment":2000},{"nctId":"NCT06160414","phase":"PHASE1","title":"A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-04-12","conditions":"Healthy","enrollment":20},{"nctId":"NCT06533280","phase":"PHASE1","title":"VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)","status":"WITHDRAWN","sponsor":"ViiV Healthcare","startDate":"2024-08-02","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT06554821","phase":"PHASE1","title":"A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-05","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT06162169","phase":"PHASE1","title":"A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2023-11-25","conditions":"Healthy Subjects","enrollment":66},{"nctId":"NCT06594159","phase":"PHASE1","title":"A Study of LY4065967 in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-10-22","conditions":"Healthy","enrollment":59},{"nctId":"NCT04211272","phase":"PHASE1","title":"A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2020-01-14","conditions":"Healthy","enrollment":47},{"nctId":"NCT04542382","phase":"PHASE1","title":"Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-10-28","conditions":"Healthy Volunteers","enrollment":11},{"nctId":"NCT04824911","phase":"PHASE2","title":"Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-03-23","conditions":"Acute Stroke, Dual Antiplatelet Therapy, Statin","enrollment":376},{"nctId":"NCT04099732","phase":"PHASE1","title":"A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-10-07","conditions":"Healthy","enrollment":26},{"nctId":"NCT06191991","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)","status":"COMPLETED","sponsor":"Aligos Therapeutics","startDate":"2023-11-03","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT02611518","phase":"PHASE1","title":"A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-04-05","conditions":"Healthy","enrollment":32},{"nctId":"NCT06503679","phase":"PHASE1","title":"A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","startDate":"2024-07-16","conditions":"Healthy","enrollment":49},{"nctId":"NCT06293261","phase":"","title":"Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2020-06-27","conditions":"Hypertension, Hypercholesterolemia","enrollment":5047},{"nctId":"NCT06677957","phase":"PHASE1","title":"A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2024-11-06","conditions":"Healthy Participants","enrollment":19},{"nctId":"NCT05613426","phase":"PHASE4","title":"Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI","status":"RECRUITING","sponsor":"Henan Institute of Cardiovascular Epidemiology","startDate":"2023-04-03","conditions":"ST Elevation Myocardial Infarction (STEMI)","enrollment":330},{"nctId":"NCT05926180","phase":"PHASE1","title":"Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)","status":"COMPLETED","sponsor":"Dizal Pharmaceuticals","startDate":"2023-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":25},{"nctId":"NCT06036784","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects","status":"COMPLETED","sponsor":"MBX Biosciences","startDate":"2023-09-18","conditions":"Postbariatric Hypoglycemia","enrollment":69},{"nctId":"NCT05981365","phase":"PHASE1","title":"Voxelotor CYP and Transporter Cocktail Interaction Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-04-17","conditions":"Sickle Cell Disease","enrollment":44},{"nctId":"NCT04094519","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-01-27","conditions":"Prostate Cancer","enrollment":24},{"nctId":"NCT05788328","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-03-27","conditions":"Healthy","enrollment":16},{"nctId":"NCT05738291","phase":"PHASE1","title":"A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-05-01","conditions":"Healthy","enrollment":67},{"nctId":"NCT06111521","phase":"PHASE1","title":"A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-10-27","conditions":"Healthy","enrollment":35},{"nctId":"NCT00693589","phase":"PHASE2","title":"Effect of Homocysteine-lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2005-01","conditions":"Cardiovascular Disease, Endothelial Dysfunction","enrollment":36},{"nctId":"NCT04964544","phase":"PHASE3","title":"Technology-Assisted Cholesterol Trial in Consumers (TACTiC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-07-08","conditions":"High Cholesterol","enrollment":1196},{"nctId":"NCT05898672","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-09","conditions":"Pharmacokinetics, Healthy Volunteers","enrollment":12},{"nctId":"NCT05657613","phase":"PHASE1","title":"Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2023-01-03","conditions":"Drug Interactions","enrollment":60},{"nctId":"NCT06105255","phase":"PHASE1","title":"A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2023-05-24","conditions":"Healthy Male","enrollment":45},{"nctId":"NCT03993236","phase":"PHASE4","title":"Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke","status":"COMPLETED","sponsor":"Keun-Sik Hong","startDate":"2019-09-09","conditions":"Stroke, Ischemic","enrollment":584},{"nctId":"NCT03864042","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-02","conditions":"Advanced Solid Tumors, Metastatic Melanoma","enrollment":56},{"nctId":"NCT06601517","phase":"PHASE1","title":"A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-10","conditions":"Healthy Adult Subject, Overweight Subject","enrollment":30},{"nctId":"NCT05176314","phase":"PHASE1","title":"A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":32},{"nctId":"NCT06247748","phase":"PHASE1","title":"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects","status":"COMPLETED","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 2, Overweight","enrollment":28},{"nctId":"NCT05652660","phase":"PHASE1","title":"A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-12-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT06293742","phase":"PHASE1","title":"ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants","status":"COMPLETED","sponsor":"Eccogene","startDate":"2024-02-08","conditions":"Type 2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT05384262","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-18","conditions":"Dyslipidemia","enrollment":183},{"nctId":"NCT06475872","phase":"PHASE1","title":"Study to Evaluate the Bioequivalence of \"Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)\" and \"Crestor Tablet 5 mg (Rosuvastatin Calcium)\" in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2023-11-20","conditions":"Primary Hypercholesterolemia, Combined Hyperlipidemia","enrollment":36},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT06348290","phase":"PHASE1","title":"Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2024-04-01","conditions":"Solid Tumor, Adult","enrollment":72},{"nctId":"NCT05615012","phase":"PHASE1","title":"A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-11-11","conditions":"Healthy Participants","enrollment":76},{"nctId":"NCT03720366","phase":"PHASE1","title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":40},{"nctId":"NCT04257032","phase":"PHASE1","title":"A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-02-13","conditions":"Healthy","enrollment":28},{"nctId":"NCT01563731","phase":"PHASE4","title":"Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2013-04","conditions":"Stroke, Transient Ischemic Attack, Hypertension","enrollment":200},{"nctId":"NCT06262685","phase":"PHASE4","title":"Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2024-03-04","conditions":"Cardiovascular Diseases, Dyslipidemias, Statin Adverse Reaction","enrollment":216},{"nctId":"NCT06225635","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2022-01-01","conditions":"Hyperlipidemias","enrollment":60},{"nctId":"NCT06092931","phase":"PHASE1","title":"A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants","status":"COMPLETED","sponsor":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","startDate":"2023-10-16","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT05395117","phase":"PHASE1","title":"A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-06-30","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT04621227","phase":"PHASE1","title":"Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-12-15","conditions":"Obesity","enrollment":16},{"nctId":"NCT05624658","phase":"NA","title":"Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS","status":"UNKNOWN","sponsor":"Samara Regional Cardiology Dispensary","startDate":"2022-09-02","conditions":"Dyslipidemias","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":93,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rosuvastatin alone therapy"],"phase":"marketed","status":"active","brandName":"Rosuvastatin alone","genericName":"Rosuvastatin alone","companyName":"Gachon University Gil Medical Center","companyId":"gachon-university-gil-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin is a small molecule used in the treatment of various conditions, including hyperlipidemia. It has been studied in clinical trials for its effects on healthy participants, hypertension, and malaria, among other conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}